Zhuhai Sailong Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
April 29, 2021 at 02:54 pm
Share
Zhuhai Sailong Pharmaceutical Co.,Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 120.684 million compared to CNY 293.466 million a year ago. Operating loss was CNY 46.986 million compared to operating Income of CNY 32.490 million a year ago. Net loss was CNY 67.221 million compared to net income of CNY 27.483 million a year ago. Basic loss per share from continuing operations was CNY 0.3819 compared to basic earnings per share from continuing operations of CNY 0.1562 a year ago.
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.
SAILONG PHARMACEUTICAL GROUP CO.,LTD. 